Exelixis, Inc.

NASDAQ:EXEL

Biotechnology

Healthcare
$68.29 +0.65%

+$0.34 today

Market cap
$17.17B
Beta
0.43
P/E (TTM)
16.3
EPS (TTM)
$3.23
52W Low $33.76High $53.93

Volume 1.82M

Average 2.55M

EXEL Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Exelixis, Inc.NASDAQ: EXEL

Revenue · Q2 FY2026 · quarter ended Jul 2026

Revenue grows in line with its trailing trend

Q2 FY2026 revenue of $628.69M rose 10.6% year over year, ahead of the +9.2% change in trailing-twelve-month revenue. Sequentially, it rose 2.9% from the prior quarter. Over 3 fiscal years it compounded at +12.9% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 12 analysts of $2.56B (+10.2%) for the fiscal year ending Jan 2027, a step up from the +7.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJul 2026
$628.69M+2.9% QoQ
Last fiscal yearJan 2026
$2.32B+7.0% YoY
LTMJul 2026
$2.44B+9.2% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.6%+8.2%-2.5 pp
1 year+7.0%+10.2%+3.2 pp
3-year CAGR+12.9%+12.5%-0.4 pp
5-year CAGR+8.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
2.32B USD
Year-over-year change
+7.0%
4-year CAGR
+12.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How EXEL compares with its peers on the latest reported figures

  • EXEL's LTM Jul 2026 revenue of $2.44B is the 4th highest of the 8 companies compared; the peer median is $602.2M.
  • Its year-over-year change of +9.2% is the 4th highest of 6, against a peer median of +26.9%.
  • Over three fiscal years its annual growth of +12.9% compares with a peer median of +9.8%.
EXEL Competitors Peer median
Revenue for EXEL and competitors
Company Period LTM YoY 3-year CAGR
AZNAstraZeneca PLCLTM Sep 2026$62.17B +7.0%+9.8%
INCYIncyte CorporationLTM Jun 2026$5.82B +26.9%+14.8%
GMABGenmab A/SLTM Jun 2026$4.13B —-36.4%
EXELExelixis, Inc.LTM Jul 2026$2.44B +9.2%+12.9%
HCMHUTCHMED (China) LimitedLTM Jun 2025$602.2M -1.4%+8.9%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$299.77M +47.6%+34.8%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$217.17M +396.7%—
RVMDRevolution Medicines, Inc.LTM Jun 2026$0 ——
Peer median (excluding EXEL) $602.2M+26.9%+9.8%

Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.43B1.61B1.83B2.17B2.32B
Cost of Revenue52.87M57.91M72.55M76.22M83.7M
Gross Profit1.38B1.55B1.76B2.09B2.24B
Gross Margin96.3%96.4%96.0%96.5%96.4%
Research & Development693.72M891.81M1.04B910.41M825M
Selling, General & Admin401.72M459.86M542.71M492.13M518.73M
Operating Expenses1.1B1.35B1.59B1.49B1.36B
Depreciation & Amortization13.63M20.88M25.72M28.8M29.06M
EBITDA307.78M255.23M283.24M718.75M921.76M
EBITDA Margin21.4%15.8%15.5%33.1%39.7%
Operating Income286.67M201.48M170.89M604.62M872.19M
Operating Margin20.0%12.5%9.3%27.9%37.6%
Interest Income7.67M33.07M86.54M77.16M69.21M
Interest Expense00000
Other Income / Expenses7.49M32.87M86.64M77.02M69.02M
Income Before Tax294.15M234.35M257.52M681.64M941.21M
Pre-Tax Margin20.5%14.5%14.1%31.4%40.6%
Income Tax Expense63.09M52.07M49.76M160.37M158.64M
Net Income231.06M182.28M207.77M521.27M782.57M
Net Margin16.1%11.3%11.4%24.0%33.7%
EPS (Basic)0.730.570.651.802.88
EPS (Diluted)0.720.560.651.762.78
Weighted Avg Shares314.88M321.53M318.15M290.03M271.57M
Weighted Avg Shares (Diluted)322.36M324.56M321.46M296.13M281.86M

Exelixis, Inc.

NASDAQ:EXEL

Intrinsic Alpha fair value

Locked

Current Price

$68.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.